This is a news story, published by Gizmodo, that relates primarily to MC4R news.
For more MC4R news, you can click here:
more MC4R newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Gizmodo, you can click here:
more news from GizmodoOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
weight loss drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest weight loss news, Semaglutide news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
weight loss effortsGizmodo
•75% Informative
Semaglutide, part of a family of drugs called GLP-1 , was first approved by the FDA for the treatment of type 2 diabetes in 2017 .
One poll published in May found that one American adult in eight had been prescribed the drug.
Researchers at the University of Michigan believe they may have found a solution in the form of proteins in the nervous system.
Inhibiting MC3R or boosting MC4R in mice also found to boost weight loss by up to five times.
VR Score
71
Informative language
72
Neutral language
64
Article tone
informal
Language
English
Language complexity
57
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
6
Source diversity
6
Affiliate links
no affiliate links